ArticleOphthalmology2010
Mortality associated with resistant cytomegalovirus among patients with cytomegalovirus retinitis and AIDS.
Article in Ophthalmology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Cytomegalovirus Retinitis Across the Immunosuppression Spectrum: A Contemporary Framework for Risk Stratification, Diagnosis, and Vision-Preserving Therapy.Journal of clinical medicine · 2026Review
- A novel inhibitor of human cytomegalovirus acts through a specific antiviral mechanism that involves the helicase-primase complex.Antimicrobial agents and chemotherapy · 2026Article
- Beyond CD4: Posterior segment findings and virologic-immunologic predictors in highly active antiretroviral therapy-naïve HIV patients.Indian journal of ophthalmology · 2026Article
- Emerging Ocular Pathogen Resistance and Clinically Used Solutions: A Problem That Is More than Meets the Eye.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Clinical, molecular, and immunologic mechanisms of CMV retinitis: Evolving understanding in HIV and non-HIV immunosuppressed patients.Expert review of ophthalmology · 2025Article
- Cytomegalovirus retinitis in the highly active anti-retroviral therapy era.Annals of eye science · 2022Article
- Article
- Management of cytomegalovirus corneal endotheliitis.Eye and vision (London, England) · 2021Review
- Continuous High-Dose (6 mg) vs. Low-Dose (3 mg) Intravitreal Ganciclovir for Cytomegalovirus Retinitis After Haploidentical Hematopoietic Stem Cell Transplantation: A Randomized Controlled Study.Frontiers in medicine · 2021Article
- Digitoxin Suppresses Human Cytomegalovirus Replication via NaJournal of virology · 2018Article
- Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus.PLoS pathogens · 2016Article
- Late emergence of A594V and L595W mutations related to ganciclovir resistance in a patient with HCMV retinitis and long-term HIV progression.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2015Article
- In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action.Antimicrobial agents and chemotherapy · 2014Article
- Wnt modulating agents inhibit human cytomegalovirus replication.Antimicrobial agents and chemotherapy · 2013Article
- Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy.Ophthalmology · 2013Article
- Human cytomegalovirus inhibition by cardiac glycosides: evidence for involvement of the HERG gene.Antimicrobial agents and chemotherapy · 2012Article
- Artemisinin-derived dimer diphenyl phosphate is an irreversible inhibitor of human cytomegalovirus replication.Antimicrobial agents and chemotherapy · 2012Article
- Polymerase chain reaction-based ganciclovir resistance testing of ocular fluids for cytomegalovirus retinitis.Archives of ophthalmology (Chicago, Ill. : 1960) · 2012Article
- Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.American journal of ophthalmology · 2011Article
- An artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activities.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
objectiveTo evaluate the effect of drug-resistant cytomegalovirus (CMV) on survival among patients with CMV retinitis.
designProspective cohort study during 1993 to 2003.
participantsWe included 266 patients with AIDS and newly diagnosed CMV retinitis treated with either ganciclovir or foscarnet.
methodsData on ganciclovir and foscarnet resistance were obtained from blood and urine specimens collected at regular, predetermined intervals. The effect of resistant CMV on mortality was evaluated with a time-dependent Cox proportional hazard model.
main outcome measuresMortality.
resultsThe median survival of the entire cohort was 12.6 months. Analysis of risk factors for mortality demonstrated that resistant CMV was associated with an increased mortality (hazard ratio, 1.65; 95% confidence interval, 1.05-2.56; P = 0.032). Among the other parameters tested, only time since AIDS diagnosis was associated significantly with mortality, with a hazard ratio of 1.10 per year since AIDS diagnosis (P = 0.001).
conclusionsResistant CMV is associated with increased mortality among patients with AIDS being treated for CMV retinitis. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.